The Experts below are selected from a list of 23901 Experts worldwide ranked by ideXlab platform
Roy F P M Kruitwagen - One of the best experts on this subject based on the ideXlab platform.
-
perioperative changes in serum ca125 levels a prognostic factor for Disease Specific Survival in patients with ovarian cancer
Journal of Gynecologic Oncology, 2017Co-Authors: Nienke Zwakman, Rafli Van De Laar, Toon Van Gorp, Petra L M Zusterzeel, Marc P M L Snijders, Isabel Ferreira, Leon F A G Massuger, Roy F P M KruitwagenAbstract:Objective: In patients with advanced stage epithelial ovarian cancer (EOC) the volume of residual tumor after debulking is known as prognostic factor for Survival. We wanted to examine the relationship between postoperative decline in serum CA125 and residual Disease after cytoreductive surgery and evaluate perioperative changes in serum CA125 levels as predictor for Disease-Specific Survival. Methods: A retrospective study was conducted of patients with FIGO stage IIb-IV EOC treated with cytoreductive surgery, followed by chemotherapy between 1996 and 2010 in three hospitals in the Southeastern region of the Netherlands. Data were analyzed with the use of multilevel linear regression and Cox-proportional hazard regression models. Results: A postoperative decline in serum CA125 level of ≥80% was associated with complete primary cytoreduction (p=0.035). Univariate analyses showed favorable associations with Survival for both the degree of decline in serum CA125 and residual tumor after primary cytoreduction. In multivariate analyses the decline in serum CA125 but not the outcome of surgery remained significantly associated with better Survival (HR50%–79%=0.52 [95% CI: 0.28–0.96] and HR≥80%=0.26 [95% CI: 0.13–0.54] vs. the serum CA125 decline of <50% [p<0.001]). Conclusion: The current study, although hampered by possible biases, suggests that the perioperative decline in serum CA125 is an early biomarker that predicts Disease-Specific Survival in patients who underwent primary cytoreductive surgery for advanced stage EOC. If confirmed prospectively, the perioperative change in serum CA125 could be a better marker for residual tumor volume after primary cytoreductive surgery (and therewith Disease-Specific Survival) than the surgeons’ estimation of residual tumor volume.
-
Perioperative changes in serum CA125 levels: a prognostic factor for Disease-Specific Survival in patients with ovarian cancer.
Journal of Gynecologic Oncology, 2016Co-Authors: Nienke Zwakman, Rafli Van De Laar, Toon Van Gorp, Petra L M Zusterzeel, Marc P M L Snijders, Isabel Ferreira, Leon F A G Massuger, Roy F P M KruitwagenAbstract:Objective: In patients with advanced stage epithelial ovarian cancer (EOC) the volume of residual tumor after debulking is known as prognostic factor for Survival. We wanted to examine the relationship between postoperative decline in serum CA125 and residual Disease after cytoreductive surgery and evaluate perioperative changes in serum CA125 levels as predictor for Disease-Specific Survival. Methods: A retrospective study was conducted of patients with FIGO stage IIb-IV EOC treated with cytoreductive surgery, followed by chemotherapy between 1996 and 2010 in three hospitals in the Southeastern region of the Netherlands. Data were analyzed with the use of multilevel linear regression and Cox-proportional hazard regression models. Results: A postoperative decline in serum CA125 level of ≥80% was associated with complete primary cytoreduction (p=0.035). Univariate analyses showed favorable associations with Survival for both the degree of decline in serum CA125 and residual tumor after primary cytoreduction. In multivariate analyses the decline in serum CA125 but not the outcome of surgery remained significantly associated with better Survival (HR50%–79%=0.52 [95% CI: 0.28–0.96] and HR≥80%=0.26 [95% CI: 0.13–0.54] vs. the serum CA125 decline of
Jean Anderson Eloy - One of the best experts on this subject based on the ideXlab platform.
-
demographic trends and Disease Specific Survival in salivary acinic cell carcinoma an analysis of 1129 cases
Laryngoscope, 2014Co-Authors: Neal Patel, Saurin Sanghvi, Mohemmed N Khan, Qasim Husain, Soly Baredes, Jean Anderson EloyAbstract:Objective/Hypothesis Acinic cell carcinoma (AciCC) is a rare salivary gland malignancy that most commonly arises in the parotid gland. Characteristics of AciCC are slow growth and a long clinical course. As a rare tumor, population-based studies are limited. We analyzed the incidence and Survival for AciCC using a national population-based database. Study Design Retrospective analysis. Methods The United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry was utilized to calculate incidence and Disease-Specific Survival trends for AciCC between 1973 and 2009. Patient data were stratified according to age, gender, race, grade, and extent of Disease. Incidence trends were studied across the last 30 years and long-term Disease-Specific Survival outcomes were compared across the different demographic parameters. Results A total of 1,129 cases of AciCC were identified, comprising of 672 (59.52%) females. Incidence trend analysis revealed significant changes in yearly incidence rates from 1973 to 2009 for male gender and white and “others” races. Overall 5-year Survival was 97.15%, 10-year Survival was 93.81%, and 20-year Survival was 89.74%. Significant differences in Survival outcomes were noted for extent of Disease. Patients exhibiting distant metastasis displayed the worse long-term prognosis at 21.99% 20-year Disease-Specific Survival. Hazard ratios demonstrated a significant increase in mortality in patients with poorly differentiated, undifferentiated, and metastatic Disease. Conclusion Trends in incidence of AciCC are influenced by gender, race and age. Long-term Survival of this rare malignant tumor is influenced by gender, grade, race, and extent of Disease. Future studies need to be conducted to investigate these dynamic trends related to AciCC. Level of Evidence 2b. Laryngoscope, 124:172–178, 2014
-
Demographic trends and Disease‐Specific Survival in salivary acinic cell carcinoma: An analysis of 1129 cases
Laryngoscope, 2013Co-Authors: Neal Patel, Saurin Sanghvi, Mohemmed N Khan, Qasim Husain, Soly Baredes, Jean Anderson EloyAbstract:Objective/Hypothesis Acinic cell carcinoma (AciCC) is a rare salivary gland malignancy that most commonly arises in the parotid gland. Characteristics of AciCC are slow growth and a long clinical course. As a rare tumor, population-based studies are limited. We analyzed the incidence and Survival for AciCC using a national population-based database. Study Design Retrospective analysis. Methods The United States National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registry was utilized to calculate incidence and Disease-Specific Survival trends for AciCC between 1973 and 2009. Patient data were stratified according to age, gender, race, grade, and extent of Disease. Incidence trends were studied across the last 30 years and long-term Disease-Specific Survival outcomes were compared across the different demographic parameters. Results A total of 1,129 cases of AciCC were identified, comprising of 672 (59.52%) females. Incidence trend analysis revealed significant changes in yearly incidence rates from 1973 to 2009 for male gender and white and “others” races. Overall 5-year Survival was 97.15%, 10-year Survival was 93.81%, and 20-year Survival was 89.74%. Significant differences in Survival outcomes were noted for extent of Disease. Patients exhibiting distant metastasis displayed the worse long-term prognosis at 21.99% 20-year Disease-Specific Survival. Hazard ratios demonstrated a significant increase in mortality in patients with poorly differentiated, undifferentiated, and metastatic Disease. Conclusion Trends in incidence of AciCC are influenced by gender, race and age. Long-term Survival of this rare malignant tumor is influenced by gender, grade, race, and extent of Disease. Future studies need to be conducted to investigate these dynamic trends related to AciCC. Level of Evidence 2b. Laryngoscope, 124:172–178, 2014
Rafli Van De Laar - One of the best experts on this subject based on the ideXlab platform.
-
perioperative changes in serum ca125 levels a prognostic factor for Disease Specific Survival in patients with ovarian cancer
Journal of Gynecologic Oncology, 2017Co-Authors: Nienke Zwakman, Rafli Van De Laar, Toon Van Gorp, Petra L M Zusterzeel, Marc P M L Snijders, Isabel Ferreira, Leon F A G Massuger, Roy F P M KruitwagenAbstract:Objective: In patients with advanced stage epithelial ovarian cancer (EOC) the volume of residual tumor after debulking is known as prognostic factor for Survival. We wanted to examine the relationship between postoperative decline in serum CA125 and residual Disease after cytoreductive surgery and evaluate perioperative changes in serum CA125 levels as predictor for Disease-Specific Survival. Methods: A retrospective study was conducted of patients with FIGO stage IIb-IV EOC treated with cytoreductive surgery, followed by chemotherapy between 1996 and 2010 in three hospitals in the Southeastern region of the Netherlands. Data were analyzed with the use of multilevel linear regression and Cox-proportional hazard regression models. Results: A postoperative decline in serum CA125 level of ≥80% was associated with complete primary cytoreduction (p=0.035). Univariate analyses showed favorable associations with Survival for both the degree of decline in serum CA125 and residual tumor after primary cytoreduction. In multivariate analyses the decline in serum CA125 but not the outcome of surgery remained significantly associated with better Survival (HR50%–79%=0.52 [95% CI: 0.28–0.96] and HR≥80%=0.26 [95% CI: 0.13–0.54] vs. the serum CA125 decline of <50% [p<0.001]). Conclusion: The current study, although hampered by possible biases, suggests that the perioperative decline in serum CA125 is an early biomarker that predicts Disease-Specific Survival in patients who underwent primary cytoreductive surgery for advanced stage EOC. If confirmed prospectively, the perioperative change in serum CA125 could be a better marker for residual tumor volume after primary cytoreductive surgery (and therewith Disease-Specific Survival) than the surgeons’ estimation of residual tumor volume.
-
Perioperative changes in serum CA125 levels: a prognostic factor for Disease-Specific Survival in patients with ovarian cancer.
Journal of Gynecologic Oncology, 2016Co-Authors: Nienke Zwakman, Rafli Van De Laar, Toon Van Gorp, Petra L M Zusterzeel, Marc P M L Snijders, Isabel Ferreira, Leon F A G Massuger, Roy F P M KruitwagenAbstract:Objective: In patients with advanced stage epithelial ovarian cancer (EOC) the volume of residual tumor after debulking is known as prognostic factor for Survival. We wanted to examine the relationship between postoperative decline in serum CA125 and residual Disease after cytoreductive surgery and evaluate perioperative changes in serum CA125 levels as predictor for Disease-Specific Survival. Methods: A retrospective study was conducted of patients with FIGO stage IIb-IV EOC treated with cytoreductive surgery, followed by chemotherapy between 1996 and 2010 in three hospitals in the Southeastern region of the Netherlands. Data were analyzed with the use of multilevel linear regression and Cox-proportional hazard regression models. Results: A postoperative decline in serum CA125 level of ≥80% was associated with complete primary cytoreduction (p=0.035). Univariate analyses showed favorable associations with Survival for both the degree of decline in serum CA125 and residual tumor after primary cytoreduction. In multivariate analyses the decline in serum CA125 but not the outcome of surgery remained significantly associated with better Survival (HR50%–79%=0.52 [95% CI: 0.28–0.96] and HR≥80%=0.26 [95% CI: 0.13–0.54] vs. the serum CA125 decline of
Xavier León - One of the best experts on this subject based on the ideXlab platform.
-
Salvage surgery in head and neck cancer: External validation of predictors of Disease-Specific Survival.
Oral Oncology, 2020Co-Authors: Miquel Quer, Xavier León, Maria Casasayas, Aina Sansa, Montserrat López, Jacinto García LorenzoAbstract:Abstract Objective Salvage surgery in recurrent head and neck squamous cell carcinoma (HNSCC) is associated with poor outcomes. There is great interest to better identify suitable surgical patients. This study aimed to validate the proposal of Hamoir et al. to use three items to predict the outcomes of salvage surgery. Materials and methods Single-center analysis of 577 patients undergoing salvage surgery for recurrent HNSCC during the period 1985–2016, with a minimal follow-up of 2 years. Patients were classified according to the prediction modeling proposed by Hamoir et al. This prediction modeling is based on three predictors: the tumor site (larynx vs non-larynx), initial staging (stage I–II vs stage III–IV), and site of recurrence (local or regional vs locoregional). Results Five-year Disease-Specific Survival after salvage surgery was 54.0% (95% CI: 49.6–58.4%). Applying the prediction modeling tested, a total of 212 patients (36.7%) patients had no predictors of poor prognosis, 185 (32.1%) had one predictor, 146 (25.3%) two predictors, and 34 (5.9%) three predictors. Five-year Disease-Specific Survival for patients with none, one, two and three predictors were 82.2%, 47.2%, 29.5% and 20.2% respectively (P = 0.0001). Conclusions We have validated the prediction modeling based on the location of the tumor, initial staging and locoregional recurrence proposed by Hamoir et al. This prediction model is easy to apply and provides good information about the possibilities of success of salvage surgery.
-
Does age influence Disease-Specific Survival in patients with squamous cell carcinomas of the head and neck?
Journal of Surgical Oncology, 2020Co-Authors: Cristina Valero, Miquel Quer, Jacinto García, Ian Ganly, Jatin P. Shah, Snehal G. Patel, Xavier LeónAbstract:BACKGROUND AND OBJECTIVES: The number of patients diagnosed with head and neck squamous cell carcinoma (HNSCC) at an advanced age has increased. The aim of this study is to evaluate the age at which Disease-Specific Survival (DSS) significantly decreases in HNSCC. METHODS: We performed a retrospective study of 5469 patients with HNSCC treated at our center (1985-2016). External validation with 2082 oral squamous cell carcinomas from a collaborative institution from another continent was performed. RESULTS: We observed an orderly decrease in overall Survival as age at diagnosis increased. There were no differences in DSS based on age for patients 85 had a 2.19 times higher risk (95% CI: 1.68-2.87; P
-
does age influence Disease Specific Survival in patients with squamous cell carcinomas of the head and neck
Journal of Surgical Oncology, 2020Co-Authors: Cristina Valero, Miquel Quer, Xavier León, Jacinto García, Ian Ganly, Jatin P. Shah, Snehal G. PatelAbstract:BACKGROUND AND OBJECTIVES The number of patients diagnosed with head and neck squamous cell carcinoma (HNSCC) at an advanced age has increased. The aim of this study is to evaluate the age at which Disease-Specific Survival (DSS) significantly decreases in HNSCC. METHODS We performed a retrospective study of 5469 patients with HNSCC treated at our center (1985-2016). External validation with 2082 oral squamous cell carcinomas from a collaborative institution from another continent was performed. RESULTS We observed an orderly decrease in overall Survival as age at diagnosis increased. There were no differences in DSS based on age for patients 85 had a 2.19 times higher risk (95% CI: 1.68-2.87; P < .001). CONCLUSIONS DSS started to significantly decrease in HNSCC at 80 years old. These findings, validated in an independent cohort, indicate that chronological age on its own should not withhold curative treatment in the majority of patients with HNSCC.
Eiji Kikuchi - One of the best experts on this subject based on the ideXlab platform.
-
NUCLEAR EXPRESSION OF ARYL HYDROCARBON RECEPTOR PREDICTS Disease Specific Survival OF UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT
The Journal of Urology, 2008Co-Authors: Masaru Ishida, Eiji Kikuchi, Shuji Mikami, Takeo Kosaka, Akira Miyajima, Makio Mukai, Yasunori OkadaAbstract:199 NUCLEAR EXPRESSION OF ARYL HYDROCARBON RECEPTOR PREDICTS Disease Specific Survival OF UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT Masaru Ishida*, Eiji Kikuchi, Shuji Mikami, Takeo Kosaka, Akira Miyajima, Makio Mukai, Yasunori Okada, Mototsugu Oya. Tokyo, Japan. INTRODUCTION AND OBJECTIVE: Cigarette smoke contributes to the development of urothelial cancer (UC). The aryl hydrocarbon receptor (AhR), which is the receptor for xenobiotics such as cigarette smoke, induces the CYP1 family, which becomes involved in tumor initiation and progression. AhR overexpression is observed in a few cancers, such as lung and pancreatic cancer, but expression of AhR in UCs, including bladder cancer, has not been investigated. We detected
-
lymphovascular invasion independently predicts increased Disease Specific Survival in patients with transitional cell carcinoma of the upper urinary tract
The Journal of Urology, 2005Co-Authors: Eiji Kikuchi, Yutaka Horiguchi, Jun Nakashima, Naoki Hatakeyama, Mayuko Matsumoto, Toru Nishiyama, Masaru MuraiAbstract:ABSTRACTPurpose: We investigated the prognostic impact of lymphovascular invasion (LVI) and traditional prognostic factors for Survival in a large series of patients treated surgically for upper tract transitional cell carcinoma (TCC). We also developed a prognostic factors based model for risk stratification of upper tract TCC.Materials and Methods: We identified a study population of 173 consecutive patients treated surgically for upper tract TCC at our institution between 1980 and 2002. We compared LVI with other pathological features and determined the Disease Specific Survival rate.Results: LVI was found in 52 patients (30.1%). As tumor grade and pathological stage increased, the incidence of LVI increased significantly. LVI was found in 12 of 133 patients (9.0%) without lymph node metastasis compared with 40 of 40 patients (100%) with lymph node metastasis. Five and 10-year Disease Specific Survival rates were 84.9% and 80.4% in the absence of LVI, and 40.2% and 21.1% in the presence of LVI, respect...